AAPL 165.4 -1.34 (-0.80%)MSFT 106.08 -1.4 (-1.30%)FB 144.04 -1.32 (-0.91%)ZNGA 3.71 +0.04 (+1.23%)NVDA 146.45 -1.46 (-0.99%)WBA 78.69 -0.4 (-0.51%)GOOG 1041.79 -8.01 (-0.76%)PIH 5 -0.12 (-2.34%)
AAPL 165.4 -1.34 (-0.80%)MSFT 106.08 -1.4 (-1.30%)FB 144.04 -1.32 (-0.91%)ZNGA 3.71 +0.04 (+1.23%)NVDA 146.45 -1.46 (-0.99%)WBA 78.69 -0.4 (-0.51%)GOOG 1041.79 -8.01 (-0.76%)PIH 5 -0.12 (-2.34%)

Balance Sheet ACRX Quote AcelRx Phar

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 108 80 53
ShortTermInvest 6 0 8
Cash 113 80 60
AccountReceivab 3 6 2
Inventories 0 2 1
DeferredIncomeT 0 0 0
OtherCurrentAss 0 0 0
TotalCurrentAss 119 89 63
PPE 13 17 19
AccumulatedDepr -5 -7 -8
NetPPE 9 11 11
EquityAndOtherI 0 0 0
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 0 0 1
TotalNonCurrent 9 11 12
TotalAssets 128 100 76
ShortTermDebt 5 3 8
AccountsPayable 2 2 1
TaxesPayable 0 0 0
AccruedLiabilit 4 5 4
DeferredRevenue 3 0 0
OtherCurrentLia 0 1 1
TotalCurrentLia 13 10 14
Debt 16 19 11
DeferredTaxesLi 0 0 0
DeferredRevenue 1 4 3
OtherLTLiabilit 65 73 84
TotalNonCurrent 82 95 98
TotalLiabilitie 95 105 112
CommonStock 0 0 0
AdditionalPaidI 236 241 261
RetainedEarning -203 -246 -298
AccumulatedOthe 0 0 0
TotalStockholde 33 -5 -37
TotalLiabilitie 128 100 76
AcelRx Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AcelRx Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.